http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
FP 항암화학요법환자를 위한 표준진료지침서 및 간호기록지 개발
장선호,조선희,연미자,김매자,임선홍,전현숙,송화선,이지애,엄현정,김은실 성인간호학회 1999 성인간호학회지 Vol.11 No.4
The current patient management system has several limitations. To develop the critical pathway (CP) as a cost-effective method via continuous patient management. we investigated the medical records of 77 patients who underwent FP chemotherapy in Seoul National University Hospital from Feb. 1 to28. 1999. And the pilot study was done to 12 patients admitted to undergo the FP chemotherapy. 1. The vertical contents in the CP consisted of 7 items : assessment, activity, diet, IV therapy, medication, education and evaluation. The duration of the horizontal axis was 6 days from admission to discharge. 2. The medical performance according to the vertical axis in the preliminary CP, consisted of 72, and modified to 74 items in the final form of CP. 3. The nursing record consisted of a vertical axis of 4 items : assessment, IV therapy, medication and education. The duration of the horizontal axis was 6 days from admission to discharge of hospital days.
간세포암 환자의 종양병기 평가에 대한 Up-to-Seven Score의 임상적 유용성
정창호 ( Chang Ho Jung ),서연석 ( Yeon Seok Seo ),이재민 ( Jae Min Lee ),윤석배 ( Seok Bae Yoon ),윤태정 ( Tae Jung Yun ),임선영 ( Sun Young Yim ),안형진 ( Hyonggin An ),엄순호 ( Soon Ho Um ),김창덕 ( Chang Duck Kim ),류호상 ( Ho 대한간암학회 2014 대한간암학회지 Vol.14 No.1
Background/Aims: Up-to-seven criteria was proven to be useful for predicting prognosis after liver transplantation in patients with hepatocellular carcinoma (HCC). The aim of this study was to evaluate that up-to-seven score could be useful method for prediction of prognosis in patients with HCC who did not undergo liver transplantation. Methods: Between January 2006 and December 2008, 216 HCC patients without vascular invasion, lymph node and distant metastasis were analyzed retrospectively. We investigated the prognostic impact of laboratory findings, clinical characteristics, modified UICC T stage, and up-to-seven score in HCC. The survival analyses were performed using Kaplan-Meier Results: Two-hundred sixteen patients with HCC were included. Age was 60.1±11.3 years and 74.5% were male. Chronic hepatitis B was the most common cause of liver disease (60.6%). T stage was T1, T2, and T3 in 36 (16.7%), 118 (54.6%), and 62 (28.7%) patients, respectively. Up-to-even score was 5.5±4.0 and it was <3 (UTS 1), ≥3 and ≤7 (UTS 2), and >7 (UTS 3) in 36 (16.7%), 133 (61.6%), and 47 (21.8%) patients, respectively. The 10 (8.5%) patients of T2 stage were classified into UTS 3 and 25 (40.3%) patients of T3 stage were classified into UTS 2. The prognosis was significantly different in patients with T2 or T3 according to their UTS. Multivariate analysis showed that Child-Pugh score and UTS were significantly associated Conclusions: Up-to-seven score was useful to predict prognosis and to evaluate tumor stage in patients without vascular invasion, lymph node and distant metastasis.
고립성 골 전이를 동반한 식도편평세포암에서 동시 항암화학방사선 요법 후 완전관해를 보인 1례
김선영,서민호,최혁순,김은선,금보라,진윤태,이홍식,엄순호,김창덕,류호상,이우진,전훈재,김예지,Sun Young Kim,Min Ho Seo,Hyuk Soon Choi,Eun Sun Kim,Bora Keum,Yoon Tae Jeen,Hong Sik Lee,Soon Ho Um,Chang Duck Kim,Ho Sang Ryu,Woo Jin Lee,Hoon Jai 대한소화기암연구학회 2013 Journal of digestive cancer reports Vol.1 No.1
There is no established treatment for esophageal carcinoma with metastasis. For the metastatic esophageal squamous cell carcinoma, chemotherapy or best supportive care according to patient's performance status are accepted as an available treatment. We report a case of complete remission after concurrent chemoradiotherapy for esophageal squamous cell carcinoma with metastatic lesion in 5th thoracic vertebrae. A 57-year-old man with ongoing dysphagia and weight loss was admitted to our hospital. On the endoscopic and radiologic imaging evaluation,the patient was diagnosed as a squamous cell carcinoma of esophagus with solitary metastatic lesion in 5th thoracic vertebrae. The patient was treated with combination chemotherapy (5-fluorouracil (5-FU) and cisplatin) and concurrent radiotherapy for two months to relieve dysphagia. Because metastatic lesion in thoracic vertebrae was located near the primary esophageal tumor, the metastatic lesion could be included within the radiation field. After concurrent chemoradiotherapy, consecutive 4 cycles of chemotherapy had been carried out. Primary esophageal tumor with metastatic lymph nodes and metastatic lesion in 5th thoracic vertebrae disappeared on follow up computed tomography (CT) and positron emission tomography-CT (PET-CT). Follow up endoscopic biopsy revealed no remnant malignant cells at previous primary cancer lesion.
( Sun Young Yim ),( Soon Ho Um ),( Yeon Seok Seo ),( Yoon Tae Jeen ),( Hong Sik Lee ),( Hoon Jai Chun ),( Chang Duck Kim ),( Ho Sang Ryu ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Inactive and active phases of HBeAg negative CHB is based on HBV DNA cut off set up at 2000IU/mL. However it is difficult to distinguish the patients who remain persistently inactive even if serum DNA levels are once below this level because of frequent fluctuations of viremia. Therefore we aimed to study whether combination of HBsAg quantification (qHBsAg) and serum HBV DNA levels measurement at a single time point might identify “true inactive carriers” in treatment naive patients. Methods: A total of 133 inactive carriers (i.e HBeAg negativity, anti HBe-positivity, normal ALT levels and HBV DNA<2000 IU/mL) were enrolled and followed up for more than 12 months. Baseline clinical characteristics, qHBsAg using the ARCHITECT quantitative assay (Abbott Diagnostic, Germany), serum HBV DNA levels and biochemical factors were reviewed. Results: Out of 133 inactive carriers 92 patients remained inactive while 41 patients developed reactivation during 12 months from enrollment. Median value for baseline qHBsAg and serum HBV DNA levels were significantly lower in inactive carriers compared to CHB patients (415.55 IU/mL vs 1604.7 IU/mL, 70 IU/mL vs 627 IU/mL, both p<0.001). Baseline log qHBsAg, log HBV DNA and total bilirubin were significantly associated with reactivation (p=0.004, p=0.004, p=0.018 respectively). Age showed significant negative correlation with log qHBsAg in both phases (both p<0.01 ) while log HBV DNA showed significant correlation with log qHBsAg in inactive carriers only (p<0.001). The AUROC of combined log qHBsAg and log HBV DNA for predicting inactive carriers was 0.772. The single point combined qHBsAg (<350 IU/mL) and serum HBV DNA (<150 IU/mL) identified inactive carriers with 33.6% of sensitivity, 100% of specificity, 100% of positive predictive value and 40.2% of negative predictive value. Conclusions: This is the first study showing that single point combined serum HBV DNA levels (<150 IU/mL) and qHBsAg (<350 IU/mL) enable to identify inactive carriers with very high specificity in HBeAg negative HBV genotype C patients. Thus both qHBsAg and serum HBV DNA levels should be considered in management of CHB patients.
The Development of Evidence-Based Guideline for Diagnosis and Management of Headache in Korea
Sun Mi Kim,Young-Hoon Ko,Seoyoung Yoon,Won Sub Kang,Hye-Geum Kim,Hye Youn Park,Cheolmin Shin,Yoo Hyun Um,Soyoung Youn,Jae-Hon Lee,Seung-Ho Jang,Sang Won Jeon,Hong Jun Jeon,Seockhoon Chung,Jae-Won Choi 대한신경정신의학회 2019 PSYCHIATRY INVESTIGATION Vol.16 No.3
Objective: We aimed to develop the clinical guideline for headache by the systematic review and synthesis of existing evidence-based guidelines. The purpose of developing the guideline was to improve the appropriateness of diagnosis and treatment of headache disorder, and consequently, to improve patients’ pain control and quality of life. The guideline broadly covers the differential diagnosis and treatment of tension-type headache, migraine, cluster headache, and medication-overuse headache. Methods: This is a methodological study based on the ADAPTE methodology, including a systematic review of the literature, quality assessment of the guidelines using the Appraisal of Clinical Guidelines for REsearch & Evaluation II (AGREE II) Instrument, as well as an external review using a Delphi technique. The inclusion criteria for systematic search were as follows: topic-relevant, up-to-date guidelines including evidence from within 5 years, evidence-based guidelines, guidelines written in English or Korean, and guidelines issued by academic institutions or government agencies. Results: We selected five guidelines and conducted their quality assessment using the AGREE II Instrument. As a result, one guideline was found to be eligible for adaptation. For 13 key questions, a total of 39 recommendations were proposed with the grading system and revised using the nominal group technique. Conclusion: Recommendations should be applied to actual clinical sites to achieve the ultimate goal of this guideline; therefore, follow-up activities, such as monitoring of guideline usage and assessment of applicability of the recommendations, should be performed in the future. Further assessment of the effectiveness of the guideline in Korea is needed.
( Sun Hye Shin ),( Hye Yun Park ),( Yunjoo Im ),( Sumin Shin ),( Genehee Lee ),( Byeong-ho Jeong ),( Kyungjong Lee ),( Sang-won Um ),( Hojoong Kim ),( O Jung Kwon ),( Jong Ho Cho ),( Hong Kwan Kim ),( 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.0
Background Chronic obstructive pulmonary disease (COPD) is an established risk factor for lung cancer development, but remains largely undiagnosed and untreated before lung cancer surgery. This study aimed to evaluate the effect of perioperative bronchodilator therapy on lung function changes in patients with COPD who underwent surgical resection for non-small cell lung cancer (NSCLC). Methods Among patients with NSCLC who underwent surgical resection, patients with spirometry-defined COPD were retrospectively identified. Perioperative bronchodilator therapy was defined as use of long-acting muscarinic antagonist and/or long-acting beta-2 agonist both during the preoperative and postoperative period. Changes in forced expiratory volume in 1 s (FEV1) were compared between patients treated with and without perioperative bronchodilators. Results Among 268 patients with COPD, 112 (41.8%) received perioperative bronchodilator therapy, and 75% (84/112) were newly diagnosed with COPD ahead of lung cancer surgery. Declines in FEV1 after lung cancer surgery were alleviated by the administration of perioperative bronchodilator therapy, even after adjustments for surgical extent, thoracotomy, and preoperative baseline FEV1 (adjusted mean difference in FEV1 decline [95% CI] between patients without perioperative bronchodilator therapy and those with perioperative bronchodilator therapy ; -161.1 mL [-240.2, -82.0]; -179.2 mL [-252.1, -106.3]; -128.8 mL [-193.2, -64.4] at 1, 4, and 12 months after surgery, respectively) (Figure). Conclusions Perioperative treatment with bronchodilators were effective to preserve lung function, in particular FEV1, after surgical resection for NSCLC in COPD patients. An active diagnosis of COPD and treatment with bronchodilators are required for patients with NSCLC who were scheduled to undergo surgical resection.